Your session is about to expire
← Back to Search
Radiation Therapy
Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx
N/A
Waitlist Available
Led By David V. Fried, PhD
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year after completion of imrt on last enrolled patient
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether avoiding salivary ducts when giving radiation therapy to head and neck cancer patients will improve patient-reported xerostomia symptoms.
Eligible Conditions
- Head and Neck Cancers
- Oropharyngeal Cancer
- Dry Mouth
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one year after completion of imrt on last enrolled patient
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year after completion of imrt on last enrolled patient
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Xerostomia
Secondary study objectives
Salivary Ductal Visibility
Salivary Gland Volume
Salivary Secretion Rate
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Parotid-Sparing Head & Neck RadiationExperimental Treatment1 Intervention
Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) who will be treated with parotid-sparing head \& neck radiation. MRI Sialograms will be obtained to identify salivary ductal structures and stem cells to be spared during treatment.
Find a Location
Who is running the clinical trial?
UNC Lineberger Comprehensive Cancer CenterLead Sponsor
365 Previous Clinical Trials
92,680 Total Patients Enrolled
David V. Fried, PhDPrincipal InvestigatorUniversity of North Carolina at Chapel Hill, Department of Radiation Oncology